ID
20813
Beschrijving
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product. NCT01618370
Trefwoorden
Versies (1)
- 20/03/17 20/03/17 -
Geüploaded op
20 marzo 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Radium-223 Dichloride (Alpharadin) DRKS00006460 NCT01618370 in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases (Study Medication)
Radium 223 Dichloride (Alpharadin) - Study Medication
- StudyEvent: ODM
Similar models
Radium 223 Dichloride (Alpharadin) - Study Medication
- StudyEvent: ODM
C1948053 (UMLS CUI [1,2])
C0599112 (UMLS CUI [1,2])
C0444686 (UMLS CUI [1,2])
C0034553 (UMLS CUI [1,2])
C0585032 (UMLS CUI [1,2])
C1706071 (UMLS CUI [1,2])
C0585032 (UMLS CUI [1,3])
C1706071 (UMLS CUI [1,2])
C0580203 (UMLS CUI [1,3])
C0580203 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,2])